Tarlatamab

Routes of
administrationIntravenousDrug classAntineoplasticATC codeLegal statusLegal status IdentifiersCAS NumberDrugBankUNIIKEGGChemical and physical dataFormulaC₄₆₆₄H₇₁₃₉N₁₂₅₉O₁₄₅₄S₃₄Molar mass105202.82 g·mol⁻¹

Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extended-scale small cell lung cancer.^[1] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.^[1]

The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.^[2]

It was approved for medical use in the United States in May 2024.^[2][3]

Medical uses

Tarlatamab is indicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.^[1][2]

Adverse effects

The prescribing information for tarlatamab includes a boxed warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).^[1]

The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.^[2] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium.^[2]

History

Efficacy was evaluated in 99 participants with relapsed/refractory extensive stage small cell lung cancer with disease progression following platinum-based chemotherapy enrolled in DeLLphi-301 [NCT05060016], an open-label, multicenter, multi-cohort study.^[2] Participants with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, and active immunodeficiency were excluded.^[2] Participants received tarlatamab until disease progression or unacceptable toxicity.^[2]

The FDA granted the application for tarlatamab priority review, breakthrough therapy, and orphan drug designations.^[2]

Society and culture

Names

Tarlatamab is the international nonproprietary name^[4] and the United States Adopted Name.^[5]

References

Further reading

• Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. (October 2023). "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer". The New England Journal of Medicine. 389 (22): 2063–2075. doi:10.1056/NEJMoa2307980. PMID 37861218.
• Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. (June 2023). "Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41 (16): 2893–2903. doi:10.1200/JCO.22.02823. PMC 10414718. PMID 36689692.

External links

• "Tarlatamab". NCI Drug Dictionary.
• "Tarlatamab (Code C175858)". NCI Thesaurus.
• Clinical trial number NCT05060016 for "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)" at ClinicalTrials.gov